On July 1st, FDA announced its plans to focus on eight conditions under its Patient-Focused Drug Development (PFDD) Program in 2016-2017. Of these eight conditions, one of them is Autism, an autoimmune disorder.

The PFDD is part of the Prescription Drug User Fee Act (PDUFA) and plans include more patient feedback. These interactions include the patient’s assessment of the treatment, how the disease affects them, which treatment they prefer and more.

The eight conditions the article states consist of: alopecia, autism, hereditary angioedema (melanoma), non-tuberculosis mycobacterial infections, patients who have received an organ transplant, psoriasis, neuropathic pain associated with peripheral neuropathy and sacopenia.

To read more on Alexander Gaffney’s article on FDA’s PFDD program, continue reading here.